QD Clinic: Weight Loss Changed the Course of RA Save
Dr. Bella Mehta, New York, presents this case which highlights that obesity may be a target for disease modification in rheumatoid arthritis, as part of RheumNow's "The Obesity Imperative" campaign, presented in September 2026.
Transcription
Hello everyone. I'm Bella Meta. I'm a rheumatologist in New York and I wanted to talk about a case about a patient with rheumatoid arthritis and how weight loss dramatically changed some of her outcomes.
So this is a woman in her early 60s. I diagnosed her with seropositive RA a few years ago with classic joint pain, synovitis, stiffness in the hands, wrist and knees. We started her on methotrexate and achieved good control of her arthritis.
However, she had some GI side effects to the oral methotrexate, which we switched to subcutaneous. It did help somewhat but symptoms persisted and ultimately we needed to add a biologic. She was initially very hesitant. We discussed a lot of options and then we put her on weekly tocilizumab — Actemra, at that time the brand was available. She did have a good experience with it, a pretty good response.
Over the next two or three years she was doing moderately well, mostly well controlled with some flares two to three times a year, and then some days she would just wake up with a lot of pain and stiffness. But again she was not very keen on changing meds, and for the most part she was in low disease activity.
Now a few years down after being on tocilizumab, she decided to focus on her weight, partly because she had aches and pains all over sometimes and they didn't seem to be rheumatoid arthritis related. Somehow she got very motivated. She adopted a lot of lifestyle modifications and that did help somewhat but she couldn't sustainably lose weight.
Ultimately she was started on a GLP-1 receptor agonist, semaglutide. Within 3 to 4 months she started losing weight pretty obviously — whenever she'd walk in I could sense that she was losing weight — and over the next few months she lost a substantial amount of weight.
But what happened next was very striking. As her weight decreased, her rheumatoid arthritis symptoms almost completely resolved. No morning stiffness, no joint pain. She suddenly started being very active, which is exactly what she wanted. She said that she's feeling healthier than when she was in her 20s or 30s.
Eventually she didn't even need the tocilizumab. We discontinued it after a lot of counseling, and we are still monitoring her, but she has not needed any methotrexate
also now and no tocilizumab, no methotrexate, also now and no tocilizumab. Now, um, just uh about 6 months ago she also stopped her weight loss medication, um but with lifestyle modification, you know, uh that she was doing over a sustained period of time, she's been able to maintain the weight. Again, a lot of patients who are on these drugs sometimes uh you know they'll bounce right back. But this is a patient who got active and could stay active and kept um and could keep her um diet in uh in check.
So I think this is sort of one of the stories that strikes me as most promising because um you know was obesity in the first place contributing to her inflammatory burden. Um and again you know especially for me we often think about obesity as a co-morbidity with rheumatoid arthritis. Um but we know that obesity itself uh is characterized by low-grade inflammation.
So you know the the fat cells or the adipose tissue functions as an active organ essentially but we don't think, at least I don't uh, I never used to think of it like that. I know it produces inflammatory mediators like TNF, IL-6, leptin and other adipokines uh which can influence immune pathways which are known to be involved in inflammatory arthritis.
So um you know this is clinically relevant because patients with obesity and rheumatoid arthritis often report higher levels of pain, more disability, um you know more disease activity and this is known in the literature right. Um you know there was a recent retrospective study I think in RMD Open which uh looked at patients with RA and obesity and um you know these patients uh who were treated with um uh semaglutide or tirzepatide uh were associated with significant reductions in all the measures that we sort of care about in RA which is pain, ESR, CRP and disease activity.
Uh so again sort of my key takeaway point is that weight loss should be viewed as complementary to disease modifying therapy, um obviously not a replacement to it but can make a huge difference in patients. Um and and you know instead of just focusing on one thing that we're treating we have to sort of broaden our horizons too. Um and again weight reduction does reduce the mechanical burden of joints for her like her knee joint, uh improved mobility or um you know decrease in systemic inflammation because at the end of it we care about the overall quality of life um and better outcomes.
Um, further, another big teaching point I think is that while weight loss itself likely contributed to the patient's
improvement, there is a lot of new evidence coming up that GLP-1 receptor agonists may also have direct anti-inflammatory effects on the synovium itself. It suggests that patients with inflammatory arthritis like rheumatoid arthritis as well as obesity, GLP-1 agonists can be treating inflammation irrespective of the weight loss that it's causing. So again there's a lot of studies coming on the way for this, including some basic science studies looking into this, and again because GLP-1, if it's showing that it's suppressing TNF and IL-6, we know those are important in RA.
Again, I think GLP-1 therapies are also changing the conversations I have. Patients who come to me and talk about this — it's becoming an easier conversation, because historically we treated obesity as a comorbidity. Again, that's something that I take away from this patient a lot more, and I feel like this was somebody who started taking these meds right when this whole surge of GLP-1 happened. And again, this patient did not just lose weight — she experienced improved function, symptoms are better, overall quality of life is better.
As research is evolving, cases like this along with new clinical data and refocusing that obesity may represent more than just a cardiovascular risk factor or a metabolic condition — especially in our patients — might be important. So with that I want to leave you with the one-liner I would say is that obesity may be a target for disease modification in rheumatoid arthritis. And if that's something that you start talking to a lot of your patients about, you will start seeing better outcomes.
So with that, signing off — this is Bella Mehta, and follow me for more updates on Twitter.
So this is a woman in her early 60s. I diagnosed her with seropositive RA a few years ago with classic joint pain, synovitis, stiffness in the hands, wrist and knees. We started her on methotrexate and achieved good control of her arthritis.
However, she had some GI side effects to the oral methotrexate, which we switched to subcutaneous. It did help somewhat but symptoms persisted and ultimately we needed to add a biologic. She was initially very hesitant. We discussed a lot of options and then we put her on weekly tocilizumab — Actemra, at that time the brand was available. She did have a good experience with it, a pretty good response.
Over the next two or three years she was doing moderately well, mostly well controlled with some flares two to three times a year, and then some days she would just wake up with a lot of pain and stiffness. But again she was not very keen on changing meds, and for the most part she was in low disease activity.
Now a few years down after being on tocilizumab, she decided to focus on her weight, partly because she had aches and pains all over sometimes and they didn't seem to be rheumatoid arthritis related. Somehow she got very motivated. She adopted a lot of lifestyle modifications and that did help somewhat but she couldn't sustainably lose weight.
Ultimately she was started on a GLP-1 receptor agonist, semaglutide. Within 3 to 4 months she started losing weight pretty obviously — whenever she'd walk in I could sense that she was losing weight — and over the next few months she lost a substantial amount of weight.
But what happened next was very striking. As her weight decreased, her rheumatoid arthritis symptoms almost completely resolved. No morning stiffness, no joint pain. She suddenly started being very active, which is exactly what she wanted. She said that she's feeling healthier than when she was in her 20s or 30s.
Eventually she didn't even need the tocilizumab. We discontinued it after a lot of counseling, and we are still monitoring her, but she has not needed any methotrexate
also now and no tocilizumab, no methotrexate, also now and no tocilizumab. Now, um, just uh about 6 months ago she also stopped her weight loss medication, um but with lifestyle modification, you know, uh that she was doing over a sustained period of time, she's been able to maintain the weight. Again, a lot of patients who are on these drugs sometimes uh you know they'll bounce right back. But this is a patient who got active and could stay active and kept um and could keep her um diet in uh in check.
So I think this is sort of one of the stories that strikes me as most promising because um you know was obesity in the first place contributing to her inflammatory burden. Um and again you know especially for me we often think about obesity as a co-morbidity with rheumatoid arthritis. Um but we know that obesity itself uh is characterized by low-grade inflammation.
So you know the the fat cells or the adipose tissue functions as an active organ essentially but we don't think, at least I don't uh, I never used to think of it like that. I know it produces inflammatory mediators like TNF, IL-6, leptin and other adipokines uh which can influence immune pathways which are known to be involved in inflammatory arthritis.
So um you know this is clinically relevant because patients with obesity and rheumatoid arthritis often report higher levels of pain, more disability, um you know more disease activity and this is known in the literature right. Um you know there was a recent retrospective study I think in RMD Open which uh looked at patients with RA and obesity and um you know these patients uh who were treated with um uh semaglutide or tirzepatide uh were associated with significant reductions in all the measures that we sort of care about in RA which is pain, ESR, CRP and disease activity.
Uh so again sort of my key takeaway point is that weight loss should be viewed as complementary to disease modifying therapy, um obviously not a replacement to it but can make a huge difference in patients. Um and and you know instead of just focusing on one thing that we're treating we have to sort of broaden our horizons too. Um and again weight reduction does reduce the mechanical burden of joints for her like her knee joint, uh improved mobility or um you know decrease in systemic inflammation because at the end of it we care about the overall quality of life um and better outcomes.
Um, further, another big teaching point I think is that while weight loss itself likely contributed to the patient's
improvement, there is a lot of new evidence coming up that GLP-1 receptor agonists may also have direct anti-inflammatory effects on the synovium itself. It suggests that patients with inflammatory arthritis like rheumatoid arthritis as well as obesity, GLP-1 agonists can be treating inflammation irrespective of the weight loss that it's causing. So again there's a lot of studies coming on the way for this, including some basic science studies looking into this, and again because GLP-1, if it's showing that it's suppressing TNF and IL-6, we know those are important in RA.
Again, I think GLP-1 therapies are also changing the conversations I have. Patients who come to me and talk about this — it's becoming an easier conversation, because historically we treated obesity as a comorbidity. Again, that's something that I take away from this patient a lot more, and I feel like this was somebody who started taking these meds right when this whole surge of GLP-1 happened. And again, this patient did not just lose weight — she experienced improved function, symptoms are better, overall quality of life is better.
As research is evolving, cases like this along with new clinical data and refocusing that obesity may represent more than just a cardiovascular risk factor or a metabolic condition — especially in our patients — might be important. So with that I want to leave you with the one-liner I would say is that obesity may be a target for disease modification in rheumatoid arthritis. And if that's something that you start talking to a lot of your patients about, you will start seeing better outcomes.
So with that, signing off — this is Bella Mehta, and follow me for more updates on Twitter.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.